COMP <GO>
ASND vs JAZZ // ALTMAN Z-SCORE & DEBT/EQUITY
Ascendis Pharma A/S Ordinary Share (NASDAQ) VS. Jazz Pharmaceuticals plc (Ireland) (NASDAQ) • 15-METRIC TALLY: ASND 9
— JAZZ 2
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ASND
LAST: $248.98 (-0.91%) • MKT CAP: $16.55B
balance-sheet
3.74
LAST: $214.44 (-0.71%) • MKT CAP: $14.02B
balance-sheet
1.97
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ASND VS. JAZZ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ASND | JAZZ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | -4.70% | +14.60 | ASND | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | 9.61% | -7.40 | JAZZ | /fcf-yield <GO> |
| Operating Margin | 13.90% | -10.10% | +24.00 | ASND | /operating-margins <GO> |
| Net Profit Margin | 10.90% | -8.30% | +19.20 | ASND | /net-margins <GO> |
| Revenue Growth (YoY) | 12.10% | 4.90% | +7.20 | ASND | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.74 | 1.97 | +1.77 | ASND | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ASND | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.3 | 48.5 | +14.80 | ASND | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 1.09 | -0.11 | JAZZ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.6x | 36.0x | -8.40 | ASND | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.55B | $14.02B | $2.53B | ASND | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ASND REV | JAZZ REV | ASND GROSS % | JAZZ GROSS % | ASND FCF | JAZZ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $4.27B | — | — | — | $1.30B |
| FY 2024 | — | $4.07B | — | — | — | $1.36B |
| FY 2023 | — | $3.83B | — | — | — | $919.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ASND // BETA 0.98
JAZZ // BETA 1.09